# US 2026/0216071 A1 · Nanoparticulate formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216071 A1
- Document ID: US20260216071A1
- Status: Published application
- Kind: A1
- Application number: 19/140,585
- Filed: 2023-12-18
- Published: 2026-07-30
- Earliest claimed: 2022-12-19
- Assignees: NewImmune II, LLC
- Applicants: Newimmune II, LLC
- Inventors: Brian HORSBURGH; Mark David MOODY
- Web page: https://patentgrep.com/patent/US20260216071A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 31/711: Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A61K 39/12: Viral antigens
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/575: {humoral response}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of, and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.

## Claims

### Claim 1

A nanoparticle for delivery of a TLR7/8 agonist and one or more polynucleotides;
the nanoparticle comprising an outer lipid shell and an inner aqueous core within the outer lipid shell;
wherein the inner aqueous core comprises the TLR7/8 agonist and the one or more polynucleotides, and wherein the inner aqueous core further comprises a cyclodextrin host molecule that is capable of reversibly forming a complex with the TLR7/8 agonist;
wherein the TLR7/8 agonist is resiquimod (R-848) or an imidazoquinoline which is an active structural analogue of resiquimod (R-848) having the molecular structure
where R1 is N or S, and R2 is H or C and where the imidazoquinoline is unsubstituted or is substituted at one or more of the indicated addition points with one or more substituents, which substituents are independently selected from branched, linear or cyclic alkyl, alkenyl, alcohol, alkylamine, alkoxy or alkoxyalkyl groups, in particular, C1-10 alkyl, cycloalkyl, aryl, alkenyl, alcohol, alkylamine, alkoxy or alkoxyalkyl groups, or hydroxyl groups, or amine groups, or N—(C1-10 alkyl)methanesulphonamide groups;
and wherein the polynucleotides comprise one or more single-stranded DNA polynucleotides having one or more CpG motifs.

### Claim 2 (depends on 1)

The nanoparticle of claim 1, wherein the inner aqueous core of the nanoparticle has a pH of at least about 6.5.

### Claim at position 3

3-5. (canceled)

### Claim 6 (depends on 1)

The nanoparticle of claim 1, wherein the TLR7/8 agonist is resiquimod (R-848), or imiquimod (R-837), or gardiquimod, or S28690, or 852-A, or 854A, or CL075, or GS-9620, or AZD8848, or VTX-2337, or GS-9688, or S-36862 or CL097, or a derivative of any of these.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The nanoparticle of claim 1, wherein the or each polynucleotide comprises at least 4 nucleotides, and/or wherein the or each polynucleotide comprises no more than 100 nucleotides.

### Claim 9 (depends on 1)

The nanoparticle of claim 1, wherein the or each polynucleotide is an oligodeoxynucleotide comprising a phosphorothioated backbone.

### Claim 10 (depends on 1)

The nanoparticle of claim 1, wherein the or each polynucleotide is a Type A (Type D) CpG oligodeoxynucleotide, or a Type B (Type K) CpG oligodeoxynucleotide, or a Type C CpG oligodeoxynucleotide, or a Type P CpG oligodeoxynucleotide.

### Claim 11 (depends on 1)

The nanoparticle of claim 1, wherein the one or more polynucleotides include CpG 1585, CpG 2216, CpG 2336, CpG 7909, CpG 1668, CpG 1826, CpG 684, ODN D-SL01, CpG 2395, ODN M362, ODN D-SL03, and/or CpG 1018.

### Claim 12 (depends on 1)

The nanoparticle of claim 1, wherein the inner aqueous core further comprises a hydrogel polymer.

### Claim 13 (depends on 1)

A nanoparticulate composition comprising a plurality of nanoparticles of claim 1.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the composition is buffered to a pH of at least about 6.5.

### Claim 15 (depends on 13)

The composition of claim 13, which is substantially free from unencapsulated (free) TLR7/8 agonist and/or unencapsulated (free) polynucleotide and/or unencapsulated (free) non-solubilised TLR7/8 agonist and/or unencapsulated (free) non-solubilised polynucleotide.

### Claim 16 (depends on 1)

A vaccine composition comprising:
(a) an immunogenic antigen that is capable of inducing an immune response and/or an immunogenic polynucleotide that encodes an antigen capable of inducing an immune response; and
(b) a vaccine adjuvant comprising the nanoparticle of claim 1; and optionally
(c) one or more additional excipients, adjuvants and/or active ingredients.

### Claim 17 (depends on 16)

The vaccine composition of claim 16,
wherein the immunogenic antigen is a viral, bacterial, fungal or disease-associated or cancer-associated antigen; and/or wherein the immunogenic polynucleotide encodes a viral, bacterial, fungal or disease-associated or cancer-associated antigen.

### Claim 18 (depends on 16)

A method for stimulating or enhancing a therapeutic or protective immune response in a patient, or for treating a proliferative disorder in a patient, comprising administering the composition of claim 16 to the patient.

### Claim 19 (depends on 18)

The method of claim 18, wherein the patient is a subject whose immune system is partially or completely suppressed.

### Claim 20 (depends on 13)

A method for manufacturing a nanoparticulate composition of claim 13, comprising the sequential steps of:
(a) solubilising said TLR7/8 agonist and said one or more polynucleotides in aqueous solution at a pH buffered to about pH 6 or below; followed by
(b) combining the resulting aqueous solution with lipids to form nanoparticles having a lipid shell and an inner aqueous core within the lipid shell, where the inner aqueous core comprises said TLR7/8 agonist and said one or more polynucleotides; followed by
(c) increasing the buffered pH of the composition to about pH 6.5 or above.

### Claim 21 (depends on 20)

The method of claim 20, wherein step (a) comprises solubilising said TLR7/8 agonist with the cyclodextrin host molecule in aqueous solution at a pH buffered to about pH 6 or below, such as to allow the formation of an inclusion complex between said TLR7/8 agonist and the host molecule.

### Claim 22 (depends on 20)

The method of claim 20, wherein the buffered pH of the composition is increased in step (c) by diafiltration or buffer exchange.

### Claim 23 (depends on 20)

The method of claim 20, further comprising a step of adding a hydrogel polymer, between step (a) and step (b), or between step (b) and step (c), or after step (c).

### Claim 24 (depends on 20)

The method of claim 20, wherein step (a) involves solubilising said TLR7/8 agonist and said one or more polynucleotides in aqueous solution in the presence of a hydroxyacid, optionally in the presence of the cyclodextrin host molecule; and/or wherein step (a) involves combining said TLR7/8 agonist with the cyclodextrin host molecule in solution at a pH between about 4 to 5.5.

### Claim 25 (depends on 20)

The method of claim 20, further comprising reducing unencapsulated (free) TLR7/8 agonist and/or unencapsulated (free) polynucleotide from the nanoparticle composition of (b), after step (b) and before step (c).
